The global vaccine refrigerators market, valued at US$ 1.29 billion in 2024, is projected to grow to US$ 2.50 billion by 2033, according to DataM Intelligence. The forecast represents a compound annual growth rate (CAGR) of 7.6% between 2025 and 2033.
Growth is being driven by expanding global immunization programs and the need for reliable cold storage of vaccines. Most vaccines, including those for measles, polio, HPV, and COVID-19 boosters, must be stored at 2°C to 8°C. Initiatives such as WHO’s Immunization Agenda 2030 and Gavi’s Cold Chain Equipment Optimization Platform (CCEOP) have led to large-scale deployments of WHO-prequalified refrigerators in low- and middle-income countries.
The cold chain vaccine refrigerators segment held the largest market share in 2024 at 67.21%, supported by donor-funded deployments of solar direct-drive units, ice-lined refrigerators, and portable carriers. Standard 2°C to 8°C medical refrigerators also dominated with a 66.83% share, reflecting their critical role in immunization programs worldwide.
North America led the market in 2024 with a 44.13% share, driven by strong healthcare infrastructure and strict vaccine storage regulations. The Asia-Pacific region is expected to see significant growth, supported by government immunization programs and the rollout of solar-powered refrigeration in remote areas.
DataM Intelligence identified Haier Biomedical, Thermo Fisher Scientific, B Medical Systems, PHC Corporation, Cardinal Health, Dulas Ltd., Godrej, and Blue Star Limited among the major companies active in the market. These manufacturers are focusing on energy efficiency, IoT-enabled monitoring, and green refrigerants to reduce vaccine wastage and strengthen cold chain systems.
